Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
CMMB
Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd DRC (CMMB) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.4
/ 5.0
C
Value
C+
Factor Score
2.7
/ 5.0
Growth
C
Factor Score
2.3
/ 5.0
Profitability
C+
Factor Score
2.8
/ 5.0
Momentum
C
Factor Score
2.4
/ 5.0
Revisions
C-
Factor Score
1.9
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
0.0
EV / EBITDA
0.3
Rev Growth YoY
0.0%
Gross Margin
N/A
Price Return 3M
3.7%
Price Return 12M
-59.0%
Catalyst Signal
0.00
Market Cap
N/A
TTM Revenue
N/A
Price / Sales
0.0
ROE
-70.6%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | C (2.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.4) |
| 2026-08-04 | C+ (2.7) | C (2.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.4) |
| 2026-08-03 | C+ (2.7) | C (2.4) | C- (2.1) | C (2.4) | C- (2.0) | C (2.3) |
| 2026-08-02 | C+ (2.7) | C (2.4) | C- (2.0) | C (2.4) | C- (1.9) | C (2.3) |